A method of reducing systemic chronic inflammation in a subject by administering a composition capable of reducing the expression level of inflammatory biomarkers.

A method of reducing systemic chronic inflammation in a subject by administering a composition capable of reducing the expression level of inflammatory biomarkers.

The present disclosure relates to compositions, articles of manufacture, methods of preparation thereof, methods of use thereof, etc., for enhancement of sexual pleasure, conditions, disorders, and diseases related to reproductive physiology and systems, especially of mammalian females.

The present disclosure relates to compositions, articles of manufacture, methods of preparation thereof, methods of use thereof, etc., for enhancement of sexual pleasure, conditions, disorders, and diseases related to reproductive physiology and systems, especially of mammalian females.

The present disclosure relates to compositions, articles of manufacture, methods of preparation thereof, methods of use thereof, etc., for enhancement of sexual pleasure, conditions, disorders, and diseases related to reproductive physiology and systems, especially of mammalian females.

Provided are a cognitive function improving agent effective for improving cognitive function such as memory and learning ability, and a method for evaluating or selecting the cognitive function improving agent. The cognitive function improving agent comprises a GIP function inhibitor as an active ingredient.

The present invention relates to a liquid pharmaceutical composition for oral administration in the form of suspension which comprises the combination of ibuprofen and phenylephrine, or a pharmaceutically acceptable salt thereof, as active substances, and hypromellose, xanthan gum, liquid maltitol, glycerine and water. The composition is stable, has good organoleptical properties and shows excellent pharmacokinetic profile, providing quick absorption of the drugs. The present invention also relates to the use of the composition for treating the symptoms of flu and common cold, particularly in adults and in children over 7 years.

The present invention relates to a liquid pharmaceutical composition for oral administration in the form of suspension which comprises the combination of ibuprofen and phenylephrine, or a pharmaceutically acceptable salt thereof, as active substances, and hypromellose, xanthan gum, liquid maltitol, glycerine and water. The composition is stable, has good organoleptical properties and shows excellent pharmacokinetic profile, providing quick absorption of the drugs. The present invention also relates to the use of the composition for treating the symptoms of flu and common cold, particularly in adults and in children over 7 years.

The present invention is directed to a composition comprising a cannabinoid and lycopene, kits comprising same, and methods of using same, such as for treating a subject afflicted with inflammation.

The present invention is directed to a composition comprising a cannabinoid and lycopene, kits comprising same, and methods of using same, such as for treating a subject afflicted with inflammation.